Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy

Gene Therapy

Volumn 11, Issue 3, 2004, Pages 325-335

  Stabile, L P ^a,b   Lyker, J S ^a   Huang, L ^c   Siegfried, J M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antisense; c Met; Growth factors; Liposomes; Lung cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; RIBONUCLEASE; RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL NUCLEAR RNA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE CONSTRUCT; GENE SEQUENCE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEIC ACID PROBE; PATHOLOGY; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TREATMENT OUTCOME; TUMOR CELL; TUMOR XENOGRAFT; XENOGRAFT;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DOWN-REGULATION; FEMALE; GENE THERAPY; HUMANS; IMMUNOCOMPROMISED HOST; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PLASMIDS; PROTO-ONCOGENE PROTEINS C-MET; RNA, NEOPLASM; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 1242296133     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302169     Document Type: Article

References (74)

1. Cooper CS et al. Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts. EMBO J 1986; 10: 2623-2628.
2. Park M et al. Sequence of MET proto-oncogene cDNA has features characteristic of the tyrosine kinase family of growth factor receptors. Proc Natl Acad Sci USA 1987; 84: 379-6383.
3. Bottaro DP et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
4. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122: 1450-1459.
5. Naldini L et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991; 10: 2867-2878.
6. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990; 111: 2097-2108.
7. Stoker M, Gherardi E, Peryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 327: 239-242.
8. Rosen E et al. Smooth muscle-derived factor stimulates mobility of human tumor cells. Invasion Metas 1990; 10: 49-64.
9. Tsao MS et al. Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Differ 1993; 4: 571-579.
10. Yoshinaga Y et al. Human lung cancer cell line producing hepatocyte growth factor/scatter factor. Jpn J Cancer Res 1992; 83: 1257-1259.
11. Tokunou M et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; 158: 1451-1463.
12. Yi S, Tsao MS. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000; 2: 226-234.
13. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67: 901-908.
14. Jeffers M et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 1997; 94: 11445-11450.
15. Rong S et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12: 5152-5158.
16. Di Renzo MF et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000; 19: 1547-1555.
17. Lorenzato A et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 2002; 62: 7025-7030.
18. Schmidt L et al. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
19. Qiao H et al. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 2002; 86: 665-677.
20. Liang TJ et al. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 1996; 97: 2872-2877.
21. Takayama H et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94: 701-706.
22. Ghoussoub RA et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998; 82: 1513-1520.
23. Di Renzo MF et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 1994; 58: 658-662.
24. Humphrey PA et al. Hepatocyte growth factor and its receptor (c-met) in prostatic carcinoma. Am J Pathol 1995; 147: 386-396.
25. Pisters LL et al. C-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995; 154: 293-298.
26. Di Renzo MF et al. Overexpression of the c-met/HGF receptor gene in human thyroid carcinomas. Oncogene 1992; 7: 2549-2553.
27. Trovato M et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 1998; 8: 125-131.
28. Di Renzo MF et al. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995; 55: 1129-1138.
29. Di Renzo ME et al. Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1: 147-154.
30. Kaji M et al. Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 1996; 3: 393-404.
31. Nakajima M et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902.
32. Koochekpour S et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57: 5391-5398.
33. Morello S et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 2001; 189: 285-290.
34. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87: 1063-1069.
35. Yanagita K et al. Hepatocyte growth factor may act as a pumotropic factor on lung regeneration after acute lung injury. J Biol Chem 1993; 269: 21212-21217.
36. To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep 1998; 5: 1013-1024.
37. Danilkovitch-Miagkova A, Zbar B. Dysregulation of met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109: 863-867.
38. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998; 29: 75-80.
39. Huang TJ et al. Overexpression of the c-met protooncogene in human gastric carcinoma - correlation to clinical features. Acta Oncol 2001; 40: 638-643.
40. Qian CN et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002; 62: 589-596.
41. Yamashita J et al. Immunoreactive HGF is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54: 1630-1633.
42. Siegfried JM et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57: 433-439.
43. Harvey P et al. Immunoreactivity for hepatocyte growth factor and its receptor, met, in human lung carcinomas and malignant mesotholioma. J Pathol 1996; 180: 389-394.
44. Takanami I et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996; 53: 392-397.
45. Noonberg SB et al. In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation. Nucleic Acids Res 1994; 22: 2830-2836.
46. Noonberg SB, Rodeck U, Weinmann R, Herlyn M. Stable transfection of human malignant melanoma cells with basic fibroblast growth factor antisense cDNA. Ann NY Acad Sci 1992; 660: 293-294.
47. Siegfried JM et al. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther 1999; 12: 291-302.
48. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
49. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280-285.
50. He Y, Huang L. Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter. Cancer Res 1997; 57: 3993-3999.
51. He Y et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998; 90: 1080-1087.
52. Sauterer RA, Goyal A, Zieve GW. Cytoplasmic assembly of small nuclear ribonucleoprotein particles from 6 S and 20 S RNA-free intermediates in L929 mouse fibroblasts. J Biol Chem 1990; 265: 1048-1058.
53. Singh-Kaw P, Zarnegar R, Siegfried JM. Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells. Am J Physiol 1995; 268: L1012-L1020.
54. Kunkel GR, Pederson T. Transcription of a human U6 small nuclear RNA gene in vivo withstands deletion of intragenic sequences but not of an upstream TATATA box. Nucleic Acids Res 1989; 17: 7371-7379.
55. Endo S et al. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther 2000; 7: 1906-1914.
56. Grandis JR et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-4232.
57. Hyde SC et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000; 7: 1156-1165.
58. Hortobagyl GN et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 4183-4184.
59. Villaret D et al. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002; 24: 661-669.
60. Webb CP et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000; 60: 342-349.
61. Maulik G et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8: 620-627.
62. Bardelli A et al. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem 1999; 274: 29274-29281.
63. Abounader R et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999; 91: 1548-1556.
64. Abounader R et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002; 16: 108-110.
65. Jiang WG et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-Met and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001; 7: 2555-2562.
66. Atabey N et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001; 276: 14308-14314.
67. Sachs M et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J Cell Biol 2000; 150: 1375-1384.
68. Gual P et al. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000; 19: 1509-1518.
69. Nakaigawa N, Weirich G, Schmidt L, Zbar B. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. Oncogene 2000; 19: 2996-3002.
70. Morotti A et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002; 21: 4885-4893.
71. Baatar D et al. Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation. Am J Pathol 2002; 160: 963-972.
72. Chen JH, Liu TY, Wu CW, Chi CW. Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression. Med Hypothesis 2001; 57: 503-505.
73. Qian LW et al. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer 2003; 104: 542-549.
74. Nemunaitis J et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 2000; 18: 609-622.